Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron Group presents positive stroke data to US conference

Lead investigator, Professor Keith Muir, updated on progress at the American Heart Association International Stroke Conference in Los Angeles
ReNeuron Group presents positive stroke data to US conference
The company's treatment offers hope for people suffering disability as a result of a stroke

ReNeuron Group PLC (LON:RENE) said positive long-term data on its CTX cell therapy for stroke was presented at the American Heart Association International Stroke Conference in Los Angeles on Thursday.

Professor Keith Muir, of the Queen Elizabeth University Hospital, Glasgow, and Principal Investigator for ReNeuron’s PISCES II study, told the audience that upper limb functional recovery was “durable and maintained” out to 12 months post-treatment.

WATCH: ReNeuron pleased to secure podium presentation for stroke data at US conference

A total of 30% of patients responded when assessed using the ARAT scale, a measure of upper limb mobility.

Data was also presented showing a response rate in 30% of people at 12 months post-treatment of at least a one point improvement on the modified Rankin Scale. This is a seven-point global measure of disability or dependence upon others in carrying out activities of daily living.

A one-point improvement is proven to be clinically meaningful for patients, both in terms of quality of life and healthcare resources needed to care for them.

READ: ReNeuron opens US office ahead of clinical trials

Analysis of a subgroup of patients who had residual upper limb movement showed an “appreciably higher response rate” of 43% when measured using the modified Rankin scale.

ReNeuron shares were down 0.5% to 136.8p in late afternoon trading on Friday.

--Updates for share price and video link--

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
cancer
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use